Literature DB >> 33813592

An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation.

Wenjie Miao1, Pei Nie2, Guangjie Yang3, Yangyang Wang1, Lei Yan1, Yujun Zhao1, Ting Yu4, Mingming Yu1, Fengyu Wu1, Wei Rao5,6, Zhenguang Wang7.   

Abstract

PURPOSE: To construct an FDG PET/CT metabolic parameter-based model to predict early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT).
METHODS: A total of 62 patients with HCC after LT were enrolled with a follow-up period of 1 year. Basic clinical, pathology, and laboratory data, CT features (CPLC), and PET metabolic parameters (CPLCP) were collected for model construction. A CPLC nomogram without metabolic parameters and a CPLCP nomogram with metabolic parameters were established. The net reclassification index (NRI) and integrated discrimination improvement (IDI) of the two models were calculated. The constructed model was compared with Milan criteria and University of California San Francisco (UCSF) criteria. The time-dependent area under the receiver operating characteristic curve (time-AUC) was used to compare the efficiency of the models, and the bootstrap method was used to for verification. Harrell's concordance index (C-index) was used to evaluate the performance of these models. Decision curve analysis (DCA) was used to evaluate the clinical practicability of each model.
RESULTS: Thirty out of 62 patients experienced a recurrence during the 1-year follow-up. BCLC stage (P = 0.009), MVI (P = 0.032), AFP (P = 0.004), CTdmax (P = 0.033), and MTV (P = 0.039) were the independent predictors. The CPLC nomogram and the CPLCP nomogram were established. Compared with the CPLC nomogram, the NRI of the CPLCP nomogram increased by 38.98% (95% CI = -18.77-60.43%) and the IDI increased by 4.40% (95% CI = -1.00-16.62%). The AUC value of the CPLCP nomogram was higher than those of Milan criteria and UCSF criteria in the time-AUC curve. Moreover, the CPLCP nomogram had a higher C-index (0.774) than other models. Finally, the DCA curve showed that clinical practicability of the CPLCP nomogram outperformed the Milan criteria and UCSF criteria.
CONCLUSIONS: The CPLCP nomogram combining basic clinical data, pathology data, laboratory data, CT features, and PET metabolic parameters showed good efficacy and high clinical practicability in predicting the early recurrence of HCC after LT.

Entities:  

Keywords:  Early recurrence; Hepatocellular carcinoma; Liver transplantation; Positron emission tomography/computed tomography

Year:  2021        PMID: 33813592     DOI: 10.1007/s00259-021-05328-w

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  42 in total

Review 1.  Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.

Authors:  Nicola de'Angelis; Filippo Landi; Maria Clotilde Carra; Daniel Azoulay
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

2.  Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation: Impact of Treatment Modality and Recurrence Characteristics.

Authors:  Adam S Bodzin; Keri E Lunsford; Daniela Markovic; Michael P Harlander-Locke; Ronald W Busuttil; Vatche G Agopian
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

Review 3.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

4.  Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?

Authors:  Elena Fernandez-Sevilla; Marc-Antoine Allard; Jasmijn Selten; Nicolas Golse; Eric Vibert; Antonio Sa Cunha; Daniel Cherqui; Denis Castaing; René Adam
Journal:  Liver Transpl       Date:  2017-04       Impact factor: 5.799

5.  Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation.

Authors:  Nicolas Goldaracena; Andre Gorgen; Adam Doyle; Bettina E Hansen; Koji Tomiyama; Wei Zhang; Anand Ghanekar; Les Lilly; Mark Cattral; Zita Galvin; Markus Selzner; Mamatha Bhat; Nazia Selzner; Ian McGilvray; Paul D Greig; David R Grant; Gonzalo Sapisochin
Journal:  J Hepatol       Date:  2019-01-08       Impact factor: 25.083

6.  Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis.

Authors:  Wenhua Liang; Linwei Wu; Xiaoting Ling; Paul M Schroder; Weiqiang Ju; Dongping Wang; Yushu Shang; Yuan Kong; Zhiyong Guo; Xiaoshun He
Journal:  Liver Transpl       Date:  2012-10       Impact factor: 5.799

7.  Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.

Authors:  G Sapisochin; N Goldaracena; S Astete; J M Laurence; D Davidson; E Rafael; L Castells; C Sandroussi; I Bilbao; C Dopazo; D R Grant; J L Lázaro; M Caralt; A Ghanekar; I D McGilvray; L Lilly; M S Cattral; M Selzner; R Charco; P D Greig
Journal:  Ann Surg Oncol       Date:  2014-12-04       Impact factor: 5.344

Review 8.  Liver transplantation for hepatocellular carcinoma: Management after the transplant.

Authors:  Elizabeth C Verna; Yuval A Patel; Avin Aggarwal; Archita P Desai; Catherine Frenette; Anjana A Pillai; Reena Salgia; Anil Seetharam; Pratima Sharma; Courtney Sherman; Georgios Tsoulfas; Francis Y Yao
Journal:  Am J Transplant       Date:  2019-12-09       Impact factor: 8.086

9.  OPTN/SRTR 2018 Annual Data Report: Liver.

Authors:  A Kwong; W R Kim; J R Lake; J M Smith; D P Schladt; M A Skeans; S M Noreen; J Foutz; E Miller; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2020-01       Impact factor: 8.086

10.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

View more
  3 in total

1.  Metabolic tumor volume predicts long-term survival after transplantation for unresectable colorectal liver metastases: 15 years of experience from the SECA study.

Authors:  Harald Grut; Pål-Dag Line; Trygve Syversveen; Svein Dueland
Journal:  Ann Nucl Med       Date:  2022-10-14       Impact factor: 2.258

2.  CT-Based Radiomics for the Recurrence Prediction of Hepatocellular Carcinoma After Surgical Resection.

Authors:  Fang Wang; Qingqing Chen; Yuanyuan Zhang; Yinan Chen; Yajing Zhu; Wei Zhou; Xiao Liang; Yunjun Yang; Hongjie Hu
Journal:  J Hepatocell Carcinoma       Date:  2022-05-23

3.  Predicting the Recurrence of Hepatocellular Carcinoma after Primary Living Donor Liver Transplantation Using Metabolic Parameters Obtained from 18F-FDG PET/CT.

Authors:  Sungmin Kang; Joo Dong Kim; Dong Lak Choi; Byungwook Choi
Journal:  J Clin Med       Date:  2022-01-12       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.